SCHEMBL2390983

SCHEMBL2390983

C[C@H](NC(=O)OC(C)(C)C)C(=O)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
GAA P10253 5/20 0.55
KDM4E B2RXH2 1/20 0.55
GLA P06280 1/20 0.55
HPGD P15428 1/20 0.55
ALDH1A1 P00352 6/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MGLL Q99685 2/20 0.49
PPARG P37231 1/20 0.47
PPARA Q07869 1/20 0.47
HTR2A P28223 1/20 0.45
EPHX2 P34913 1/20 0.45
BCL9 O00512 1/20 0.45
CTNNB1 P35222 1/20 0.45
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29401387 1.00 MAPT (0.55) MAPTGAAKDM4EGLAHPGD
SCHEMBL2390989 1.00 MAPT (0.55) MAPTGAAKDM4EGLAHPGD
SCHEMBL24058871 0.90 MGLL (0.52) MAPTGAAKDM4EGLAHPGD
SCHEMBL19871006 0.90 MGLL (0.52) MAPTGAAKDM4EGLAHPGD
SCHEMBL30184764 0.89 KDM4E (0.64) MAPTGAAKDM4EGLAHPGD
SCHEMBL23493265 0.89 KDM4E (0.64) MAPTGAAKDM4EGLAHPGD
SCHEMBL23493263 0.89 KDM4E (0.64) MAPTGAAKDM4EGLAHPGD
SCHEMBL19668455 0.89 MAPT (0.64) MAPTGAAKDM4EGLAHPGD
SCHEMBL7341887 0.89 MAPT (0.64) MAPTGAAKDM4EGLAHPGD
SCHEMBL2032096 0.87 HTR2A (0.50) MAPTGAAKDM4EGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5073487-A Rapid assay for functional human α1 -proteinase inhibitor ATHENS RESEARCH AND TECHNOLOGY, INC. (US) 1991-12-17 US claimed
EP-0455733-A1 RAPID ASSAY FOR FUNCTIONAL HUMAN ALPHA 1?-PROTEINASE INHIBITOR ATHENS RESEARCH AND TECHNOLOGY, INC. (US) 1991-11-13 EP claimed
WO-1990008837-A1 RAPID ASSAY FOR FUNCTIONAL HUMAN ALPHA1-PROTEINASE INHIBITOR ATHENS RESEARCH AND TECHNOLOGY, INC. (US) 1990-08-09 WO claimed
CN-118791589-A Polypeptide synthesis method with long chain side chain 甘肃瑞德林生物有限公司 2024-10-18 CN disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 US disclosed
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
WO-2023178044-A1 METHOD AND POINT OF CARE DEVICE FOR MEASURING ENZYME CONCENTRATION TO MITIGATE PERISTOMAL SKIN COMPLICATIONS HOLLISTER INCORPORATED (US) 2023-09-21 WO disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 WO disclosed
US-20230121469-A1 CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) 2023-04-20 US disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 US disclosed
EP-0206076-A2 1,8-Bridged 4-quinolone-3-carboxylic acids, process for their preparation as well as medicaments containing them, and their use for the preparation of medicaments BAYER AG (DE) 1986-12-30 EP disclosed
EP-0198192-A1 7-Amino-1-(subst.cyclopropyl)-1,4 -dihydro-4-oxo-quinoline carboxylic acids, method for their preparation, and antibacterial agents containing them BAYER AG (DE) 1986-10-22 EP disclosed
EP-0167763-A1 7-Amino-1-cyclopropyl-6,8-dihalo-1,4-dihydro-4-oxo-3-quinoline-carboxylic acids, process for their preparation and bactericidal agents containing them BAYER AG (DE) 1986-01-15 EP disclosed
US-4560514-A Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds SAMUELSSON BENGT 1985-12-24 US disclosed
EP-0164619-A1 2,4,5-Trihalo or 2,3,4,5-tetrahalo benzene derivatives and process for producing them BAYER AG (DE) 1985-12-18 EP disclosed
US-4559341-A Quinolonecarboxylic acids and antibacterial agents containing these compounds BAYER AKTIENGESELLSCHAFT (DE) 1985-12-17 US disclosed
US-4556658-A 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids and antibacterial agents containing these compounds BAYER AKTIENGESELLSCHAFT (DE) 1985-12-03 US disclosed
EP-0126355-A1 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid, processes for their preparation and antibacterial agents containing them BAYER AG (DE) 1984-11-28 EP disclosed
EP-0117473-A1 Quinolone carboxylic acids, process for their preparation and antibacterial compositions containing them BAYER AG (DE) 1984-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121469-A1 CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND NAAA, ASNS, BCAT2 MAPT 3585/4885GAA 465/4885KDM4E 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.